Reaction Biology Corporation Newsroom - Profile and News Archive

MALVERN, Pa., Oct. 31, 2011 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (‘RBC’) today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain, disclosing previously unknown kinase inhibition relationships. The data set was compiled from over 100,000 independent activity assays performed with RBC’s proprietary HotSpot(SM) technology.

MALVERN, Pa., Oct. 24, 2011 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (‘RBC’), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC’s initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source.

MALVERN, Pa. (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (RBC) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC’s methyltransferase screens from 14 to 35 or more.

MALVERN, Pa. (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (RBC) today announced that it has been awarded an SBIR grant from the National Cancer Institute to create a new kinase profiling and high throughput screening method using radioisotopes and microarrays. The $940,000 grant will be used to migrate the current well-plate radioisotope methods onto RBC’s DiscoveryDot nanoliter screening platform.

CORNWALL, UK and MALVERN, PA – June 1 (SEND2PRESS NEWSWIRE) — Key Organics Ltd and Reaction Biology Corporation today announced that they have teamed up to provide a new library screening format to customers. Beginning this summer, the entire Key Bionet library of 37,500 diverse drug-like compounds will be offered for ‘rental’ screening on RBC’s DiscoveryDot(TM) platform. For the first time, customers will be able to screen the Key library without having to purchase it outright.

MALVERN, PA – Mar. 13 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (‘RBC’) today announced that it has been awarded an R01 grant from the National Institutes of Health to accelerate development of its new DiscoveryDot(TM) High Throughput Screening technology for drug discovery. The NIH grant is part of the Screening Roadmap, designed to produce innovative chemical tools for use in biological research and drug development. Out of 8 recipients of grants pursuant to the original RFA, Reaction Biology is the only private corporation to be so awarded.

MALVERN, PA and CORNWALL, UK – August 29 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (‘RBC’) and Key Organics Ltd (‘Key’) today announced that they have created a Joint Venture (‘JV’) to engage in high throughput drug discovery. The purpose of the JV is to identify a series of compounds with the potential of becoming new drugs with further research.

MALVERN, PA – August 9 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (‘RBC’) today announced that it has been awarded a Phase II SBIR grant from the National Institutes of Health to apply its new DiscoveryDot(TM) High Throughput Screening technology for drug discovery.

MALVERN, PA – June 21 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (‘RBC’) today announced that it has been awarded a Phase I SBIR grant from the National Institutes of Health to develop its new microarray kinase screening technology for testing compounds in nanoliter reactions.